Geistlich Pharma to launch new technologies
Wolhusen/Schlieren - The regeneration specialist Geistlich Pharma has developed new technologies for the implant sector. With these new products, the company has set its sights primarily on tapping into growth in emerging economies.
The regeneration specialist Geistlich Pharma, which is part of the Geistlich Group based in Schlieren in the canton of Zurich, is in the process of expanding its portfolio. As detailed in a press release, the company from Wolhusen from the canton of Lucerne intends to launch a total of 20 new products in 40 countries by the end of 2026. «Next year, Geistlich is celebrating its 175th anniversary. Our well-filled pipeline marks another milestone in the company’s history by adding new technologies, new brands, and new channels», comments Diego Gabathuler, CEO of Geistlich Pharma, in the press release.
In this context, the primary goal is to expand offerings for medical specialists, dental service organizations, general dentists and emerging markets. By offering accessible biomaterials, Geistlich will aim to tap into new markets, with a particular emphasis in this regard on these emerging economies. The company has expanded its technology portfolio through several acquisitions in recent years. As Geistlich Pharma explains in the press release, these technologies have enhanced existing solutions. In addition, reliable and affordable solutions have already been launched in emerging markets and these are now reportedly being complemented by proprietary products.
«Our high-tech biomaterials have made a significant contribution to the positive development of the implant market. With our new technologies, we will continue to spur this development», Gabathuler conlcudes.
